Safety of Lung Cryobiopsy in People With Cancer

Study summary

The purpose of this study is to find out whether a biopsy technique called transbronchial cryobiopsy (TBCB) is a safe alternative to the standard biopsy procedure (transbronchial forceps biopsy; TBFB). The study researchers think that TBCB may provide better biopsy samples to help diagnose lung disease.

Ask AI to explain this study

Start here

Key things to know

Main goalDiagnostic

This describes the study’s primary purpose.

What is being studiedTransbronchial cryobiopsy

The study team can explain what participation involves.

Who it may be forLung Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jul 1, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Memorial Sloan Kettering Cancer Center

Study sponsor

Study overview

What this study is about

Purpose: Diagnostic
Study type: Interventional
Phase: Phase 2
Sponsor: Memorial Sloan Kettering Cancer Center
Interventions being studied: Procedure: Transbronchial cryobiopsy

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

18 years of age or greater
Patients with known or suspected diagnosis of cancer and indeterminant pulmonary nodules or diffuse parenchymal lung disease with non-diagnostic clinical profiles for whom a lung biopsy is deemed useful for diagnosis.

Reasons someone may not be able to joinExclusion criteria

Patients with pulse oximetry less than 92% on oxygen delivery up to 2 L nasal cannula.
Uncorrectable coagulopathy defined as:
Platelet count \<50,000 x 10\^9/L or
prothrombin time international normalized ratio \>1.5
Known pulmonary hypertension or echocardiographic pulmonary artery systolic pressure \>50mmHg
A secure diagnosis based on clinical and high-resolution CT scan data.
Antiplatelet therapy that cannot be held for more than 5 days.
Any patient deemed unfit to undergo bronchoscopy by the proceduralist
Female patients with a positive pregnancy test within 30 days of the planned study procedure

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Memorial Sloan Kettering Cancer Center (All Protocol Activities)New York, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 1, 2026. Always confirm current availability with the study team.

View original record ↗